Humanised monoclonal antibody therapy for rheumatoid arthritis.

Humanised monoclonal antibody therapy for rheumatoid arthritis.

Monoclonal antibodies that target T cells have shown some benefit in rheumatoid arthritis although responses have not been long lasting. This is partly due to insufficient therapy consequent upon antibody immunogenicity. Use of humanised antibodies, which are expected to be less foreign to man than...

Szczegółowa specyfikacja

Opis bibliograficzny
Główni autorzy:	Isaacs, J, Watts, R, Hazleman, B, Hale, G, Keogan, M, Cobbold, S, Waldmann, H
Format:	Journal article
Język:	English
Wydane:	1992

Podobne zapisy

HUMANIZED MONOCLONAL-ANTIBODY THERAPY IN RHEUMATOID-ARTHRITIS
od: Isaacs, J, i wsp.
Wydane: (1992)

Survival of patients after lymphocytotoxic monoclonal antibody therapy for rheumatoid arthritis
od: Isaacs, J, i wsp.
Wydane: (2004)

Long-term survival after lymphocytotoxic monoclonal antibody therapy for rheumatoid arthritis
od: Isaacs, J, i wsp.
Wydane: (2005)

Long-term survival after lymphocytotoxic monoclonal antibody therapy for rheumatoid arthritis
od: Isaacs, J, i wsp.
Wydane: (2005)

Humanized monoclonal antibody treatment in rheumatoid arthritis.
od: Kyle, V, i wsp.
Wydane: (1991)

Morbidity not increased in rheumatoid arthritis patient with profound lymphopenia following CD4 monoclonal antibody therapy: comment on the article by Isaacs et al - Reply
od: Isaacs, J, i wsp.
Wydane: (2002)

TREATMENT OF RHEUMATOID-ARTHRITIS WITH HUMANIZED ANTILYMPHOCYTE ANTIBODY CAMPATH-1H
od: Watts, R, i wsp.
Wydane: (1992)

Survival of patients after lymphocytotoxic monoclonal antibody therapy for RA.
od: Isaacs, J, i wsp.
Wydane: (1998)

Monoclonal antibody therapy of diffuse cutaneous scleroderma with CAMPATH-1H.
od: Isaacs, J, i wsp.
Wydane: (1996)

Beneficial effect of monoclonal antibody to interleukin 2 receptor on activated T cells in rheumatoid arthritis.
od: Kyle, V, i wsp.
Wydane: (1989)

Aglycosyl anti-CD3 monoclonal antibody therapy in rheumatoid arthritis - Results of a pilot safety study
od: Lawson, C, i wsp.
Wydane: (2005)

Combination therapy with a TNF antagonist and a CD4 monoclonal antibody in rheumatoid arthritis. A pilot study.
od: Morgan, A, i wsp.
Wydane: (1997)

CAMPATH-1H in inflammatory arthritis.
od: Watts, R, i wsp.
Wydane: (1993)

Humanized anti-CD4 monoclonal antibody therapy of autoimmune and inflammatory disease.
od: Isaacs, J, i wsp.
Wydane: (1997)

Morbidity and mortality in rheumatoid arthritis patients with prolonged and profound therapy-induced lymphopenia.
od: Isaacs, J, i wsp.
Wydane: (2001)

A therapeutic human IgG4 monoclonal antibody that depletes target cells in humans.
od: Isaacs, J, i wsp.
Wydane: (1996)

Morbidity and mortality in rheumatoid arthritis patients with prolonged therapy-induced lymphopenia: twelve-year outcomes.
od: Lorenzi, A, i wsp.
Wydane: (2008)

Advantages of rat monoclonal antibodies.
od: Clark, M, i wsp.
Wydane: (1983)

Appropriate targets for monoclonal antibodies in the induction of transplantation tolerance.
od: Waldmann, H, i wsp.
Wydane: (2001)

Monoclonal-antibody therapy in systemic vasculitis.
od: Mathieson, P, i wsp.
Wydane: (1990)

Long-term remission of intractable systemic vasculitis with monoclonal antibody therapy.
od: Lockwood, C, i wsp.
Wydane: (1993)

HUMANIZED MONOCLONAL-ANTIBODY THERAPY FOR SYSTEMIC VASCULITIS
od: Lockwood, C, i wsp.
Wydane: (1993)

HUMANIZED MONOCLONAL-ANTIBODY (MAB) THERAPY FOR WEGENERS GRANULOMATOSIS (WG)
od: Lockwood, C, i wsp.
Wydane: (1995)

MONOCLONAL-ANTIBODIES TO HEMATOPOIETIC-CELLS
od: Waldmann, H, i wsp.
Wydane: (1982)

MONOCLONAL-ANTIBODIES IN SYSTEMIC VASCULITIS - LONG-TERM BENEFIT FROM SHORT-TERM THERAPY
od: Isaacs, J, i wsp.
Wydane: (1993)

Monoclonal antibodies for the induction of transplantation tolerance.
od: Waldmann, H, i wsp.
Wydane: (1993)

Therapeutic potential of monovalent monoclonal antibodies.
od: Cobbold, S, i wsp.
Wydane: (1984)

The use of monoclonal antibodies to achieve immunological tolerance.
od: Waldmann, H, i wsp.
Wydane: (1993)

Corrigendum: Therapeutic potential of monovalent monoclonal antibodies
od: Cobbold, S, i wsp.
Wydane: (1984)

The use of monoclonal antibodies to achieve immunological tolerance.
od: Waldmann, H, i wsp.
Wydane: (1993)

MONOCLONAL-ANTIBODIES FOR CONDITIONING PRIOR TO MARROW TRANSPLANTATION
od: Hale, G, i wsp.
Wydane: (1989)

Monoclonal antibodies for the therapeutic induction of tolerance.
od: Waldmann, H, i wsp.
Wydane: (1993)

Therapy with monoclonal antibodies by elimination of T-cell subsets in vivo.
od: Cobbold, S, i wsp.
Wydane: (1984)

Monoclonal antibodies for immunosuppression.
od: Waldmann, H, i wsp.
Wydane: (1988)

Monoclonal antibodies as agents to reinduce tolerance in autoimmunity.
od: Waldmann, H, i wsp.
Wydane: (1992)

Reprogramming the immune system for tolerance with monoclonal antibodies.
od: Cobbold, S, i wsp.
Wydane: (1990)

Purging in auto- and allografts: monoclonal antibodies which use human complement and other natural effector mechanisms.
od: Cobbold, S, i wsp.
Wydane: (1990)

Purging in auto- and allografts: monoclonal antibodies which use human complement and other natural effector mechanisms.
od: Cobbold, S, i wsp.
Wydane: (1990)

Therapy with monoclonal antibodies. An in vivo model for the assessment of therapeutic potential.
od: Isaacs, J, i wsp.
Wydane: (1992)

Monoclonal antibody therapy of chronic intraocular inflammation using Campath-1H.
od: Isaacs, J, i wsp.
Wydane: (1995)